What question did this study set out to answer?

The study aims to evaluate the impact of BCR::ABL1 transcript types on molecular responses in chronic myeloid leukemia patients undergoing frontline treatment.

December 8, 2025BloodOpen Access

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.

View Full Paper

Ask AI

Bookmark

The study aims to evaluate the impact of BCR::ABL1 transcript types on molecular responses in chronic myeloid leukemia patients undergoing frontline treatment.
Survey of chronic myeloid leukemia patients in the GIMEMA LabNet CML network
Analyzed the most frequent BCR::ABL1 transcript types over 6, 12, and 24 months
Comparative evaluation of treatment responses between imatinib and second-generation TKIs
1,471 patients with evaluable samples were included
BCR::ABL1 transcript subtype affected molecular response rates at various time points
E14a2 carriers showed significantly better responses compared to e13a2 across multiple assessments

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Survey shows different molecular response rates in chronic myeloid leukemia patients treated with imatinib or tyrosine kinase inhibitors, indicating distinct outcomes by transcript type.

Cite This Study

Marsili et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0e0 https://doi.org/10.1182/blood-2025-3755

View Full Paper

Ask AI

Bookmark

Implication

Survey shows different molecular response rates in chronic myeloid leukemia patients treated with imatinib or tyrosine kinase inhibitors, indicating distinct outcomes by transcript type.

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.

Key Points

Discussion

Implication

Cite This Study

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider